Q-omics provides the consensus-scored ATP8A1 profile across patient tissues and cancer cell-line models. ATP8A1 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, ATP8A1 is differentially expressed in 15, with the highest sampling consensus in COAD. Additionally, ATP8A1 RNA expression shows 26,176 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight KIRC, COAD, and LSCC as cancer lineages where ATP8A1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ATP8A1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ATP8A1 survival associations across molecular data types. ATP8A1 RNA expression shows survival associations in the most cancer types (25), followed by mutation status (7) and mass-spec protein abundance (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ATP8A1 RNA expression–survival associations across cancer types. High ATP8A1 expression shows favorable associations in KIRC, HNSC, MESO, ACC, LGG and SKCM. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for ATP8A1 RNA expression.
This table summarizes ATP8A1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 15, while mass-spec protein shows differences in 5. The strongest signals are observed in COAD for RNA and COAD for protein.
This table ranks reproducible tumor–normal expression differences for ATP8A1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ATP8A1 shows lower tumor expression in COAD, LUSC, LUAD, THCA, HNSC and UCEC. The COAD box plot shows higher ATP8A1 RNA expression in normal versus tumor tissue (log2 FC = −1.790, t-test p < 0.001).
This table shows molecular features associated with ATP8A1 in patient tissues and cancer cell lines. In patient samples, ATP8A1 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, ATP8A1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SKIN, while CRISPR and shRNA rows add functional-dependency signals in UPPER_AERODIGESTIVE_TRACT and BLOOD_Leukemia.
